These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 16034144)
1. Designing Personalized Antigen-Specific Immunotherapies for Autoimmune Diseases-The Case for Using Ignored Target Cell Antigen Determinants. Tian J; Song M; Kaufman DL Cells; 2022 Mar; 11(7):. PubMed ID: 35406645 [TBL] [Abstract][Full Text] [Related]
2. Immature Dendritic Cell Therapy Confers Durable Immune Modulation in an Antigen-Dependent and Antigen-Independent Manner in Nonobese Diabetic Mice. Lo J; Xia CQ; Peng R; Clare-Salzler MJ J Immunol Res; 2018; 2018():5463879. PubMed ID: 29651443 [TBL] [Abstract][Full Text] [Related]
3. Human amylin induces CD4+Foxp3+ regulatory T cells in the protection from autoimmune diabetes. Zhang XX; Qiao YC; Li W; Zou X; Chen YL; Shen J; Liao QY; Zhang QJ; He L; Zhao HL Immunol Res; 2018 Feb; 66(1):179-186. PubMed ID: 28983871 [TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine hormone amylin in diabetes. Zhang XX; Pan YH; Huang YM; Zhao HL World J Diabetes; 2016 May; 7(9):189-97. PubMed ID: 27162583 [TBL] [Abstract][Full Text] [Related]
5. Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice. Fousteri G; Jofra T; Di Fonte R; Battaglia M PLoS One; 2015; 10(6):e0127631. PubMed ID: 26080071 [TBL] [Abstract][Full Text] [Related]
8. An update on the use of NOD mice to study autoimmune (Type 1) diabetes. Chaparro RJ; Dilorenzo TP Expert Rev Clin Immunol; 2010 Nov; 6(6):939-55. PubMed ID: 20979558 [TBL] [Abstract][Full Text] [Related]
9. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Chatenoud L Nat Rev Endocrinol; 2010 Mar; 6(3):149-57. PubMed ID: 20173776 [TBL] [Abstract][Full Text] [Related]
10. Transgenically induced GAD tolerance curtails the development of early beta-cell autoreactivities but causes the subsequent development of supernormal autoreactivities to other beta-cell antigens. Tian J; Dang H; von Boehmer H; Jaeckel E; Kaufman DL Diabetes; 2009 Dec; 58(12):2843-50. PubMed ID: 19741165 [TBL] [Abstract][Full Text] [Related]
11. Antigen-based therapy for the treatment of type 1 diabetes. Tian J; Kaufman DL Diabetes; 2009 Sep; 58(9):1939-46. PubMed ID: 19720821 [No Abstract] [Full Text] [Related]
12. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Wang B; Tisch R Immunol Res; 2008; 42(1-3):246-58. PubMed ID: 19052699 [TBL] [Abstract][Full Text] [Related]
13. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Goudy KS; Wang B; Tisch R Clin Immunol; 2008 Oct; 129(1):49-57. PubMed ID: 18675592 [TBL] [Abstract][Full Text] [Related]
14. Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Wang B; Tisch R Immunol Res; 2008; 41(3):175-87. PubMed ID: 18543112 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulation of autoimmune diabetes by dendritic cells. Pechhold K; Koczwara K Curr Diab Rep; 2008 Apr; 8(2):107-13. PubMed ID: 18445352 [TBL] [Abstract][Full Text] [Related]
17. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. Baker C; Petrich de Marquesini LG; Bishop AJ; Hedges AJ; Dayan CM; Wong FS J Clin Immunol; 2008 Jul; 28(4):350-60. PubMed ID: 18311511 [TBL] [Abstract][Full Text] [Related]
18. Antigen-based therapies using ignored determinants of beta cell antigens can more effectively inhibit late-stage autoimmune disease in diabetes-prone mice. Olcott AP; Tian J; Walker V; Dang H; Middleton B; Adorini L; Washburn L; Kaufman DL J Immunol; 2005 Aug; 175(3):1991-9. PubMed ID: 16034144 [TBL] [Abstract][Full Text] [Related]